Cell-Surface Plasminogen Activation Causesa Retraction of In Vitro Cultured Human Umbilical Vein Endothelial Cell Monolayer By Grazia Conforti, Carmen Dominguez-Jimenez, Ebbe Rsnne, Gunilla Hsyer-Hansen, and Elisabetta Dejana Vascular endothelium formsa dynamic interface between blood and underlying tissues. Endothelial monolayer integrity is required for controlled vascular permeability and to preclude exposureof subendothelial cellmatrix to circulating cells. Recent studies have established that cultured human umbilical vein endothelial cells (ECs) express receptors for plasminogen (plg) and urokinase-like plasminogen activator (uPA).In the present study,we provide evidence that in EC, uPA receptor is present in focal contacts and at cell-cell contact sites. In these cells, addition of plg and uPA to confluent EC generates a retraction of the monolayer that is evidenced byloss of cell-cell contacts and increase in monolayer permeability. The phenomenon is re- versible evenafter 6 hoursof plg-uPA treatment. Inhibition of plg-uPA effect is obtained with plasmin inhibitors, as well as reagents that blodc binding of uPA plg or to the cell surface. The retractive effectof plg-uPA is concomitant to surface activation of plasminogen and to the lossof cell-cell and cell-matrix contacts. We concludethat the cell-surface activation of plg can induce EC retraction, possibiy by causing proteolysisat specific cell-cell contacts and cell-matrix sites. This process may be important in mediating the passage of metastatic tumor cells through an intact EC monolayer aswell as in regulating contactsbetween circulating cells and endothelium. 0 1994 by TheAmerican Society of Hematology. E this receptor has a very high The cloning and purification of uPAR have shown that it is a highly glycosylated polypeptide with an M, of 55,000 to 60,000,20which is linked to theplasma membrane by a glycosyl-phosphatidylinositol (GPI) membrane anchor.2'uPAR can bind both the active two-chain uPA and the proenzyme single-chain prou P A . ~Binding ~ of both forms is mediated by the NH2-termina1 growth factor domain of uPA contained in the 16-kD A Thus, the bound enzyme is catalytically active, and bound pro-uPA can be activated by plrn?' Besides localizing plg activation to the cell surface, the presence of these receptors results in strong acceleration of the rate of activation of pro-uPA to uPA by plm13925 and possibly in direct activation of pro-uPA.26 The cell-surface location protects plm from its physiologic inhibitor a2-antiplm.'3327328 These events constitute important regulatory mechanisms at sites of pericellular proteolysis. Most malignant cells have been described to overproduce plg a ~ t i v a t o r sIn . ~ ~addition,they may display autocrine saturation of uPAR with pro-uPA or active U P A . ~ In this report, we have investigated whether the uPAuPAR system could intervene in the EC retraction. To this goal, we used human umbilical vein ECs, as they have been shown to have uPAR, to produce plg-activator inhibitor type 1 (PAI-1)'5,'6,3'.32 and tohave plg binding NDOTHELIAL CELLS (ECs) play a very important role in mediating the passage to tissues of normal and malignant tumor cells. In fact, the first interaction between circulating malignant cells and their target organ occurs when they reach local capillary endothelium. Upon adhesion to ECs, malignant cells cause a retraction of the ECs that uncovers the underlying basement membrane, which becomes directly accessible for digestion and invasion.' Therefore, retraction of the ECs may be an important step in the extravasation of blood cells and of malignant (metastatic) cells. Retraction must require loosening or destruction of some cell-cell and cell-basement membrane connections, a process that might require proteases that must be active on the surface of invading-crossing cells. The most thoroughly known cell-surface proteolytic system is the plasminogen (plg) cascade regulated by the urokinase-like plasminogen activator (uPA) and its receptor (uPAR).~This system has been shown to be directly involved in several steps of tumor cell invasion3-'' and inthe inflammatory response'' because it provides the cell surface with regulated and localized plasuPAR has been identified min (plm) a ~ t i v i t y . ' ~A, 'specific ~ and cloned14and shown to be present on E C S ' ~ along , ' ~ with specific binding sites for plg/plm.17.18The plg binding site is characterized by relatively low affinity and high capacity, The and it recognizes the lysine binding-sites of ~ l g . " , ' ~ number of uPAR molecules present on cells is lower, but From the Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy; and Finsen Laboratory, Copenhagen, Denmark. Submitted April 12, 1993; accepted October 4, 1993. Supported by Associazioge Italiana per la Ricerca sul Cancro, the Italian National Research Council (CNR) Special Projects ("Biotecnologie e Biostrumentazione" and Applicazioni Cliniche della Ricerca Oncologica),and the North Atlantic Treaty Organization (Collaborative Research Grant No. 920010). Address reprint requests to Grazia Conforti, MD, Istituto di Ricerche FarmacologicheMario Negri, Via Eritrea 62,2015 7Milan0, Italy. The publication COSIS of this article were defrayed in part by page charge payment.This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate thisfact. 01994 by The American Society of Hematology. 0006-4971/94/8304-0027$3.00/0 994 MATERIALS ANDMETHODS Materials. The following reagents were used and are listed below withtheir source: human glu-plg (20.2CU/mg) and human plm (15.7 CU/mg) (Kabi Vitrum, Stockholm, Sweden); human urokinase (50-kD molecular weight, 100,000 IU/mg) (Persolv Richter) was a kind gift from LepetitSPA (Milano, Italy); human prourokinase was a kind gift from Farmitalia-Carlo Erba Srl(Nerviano, Italy);t-PA (792,000 IU/mg and 704,225 IU/mg) (BiopoolAB, Umei, Sweden); low molecular weight urokinase (33 kD,160,000 IU/mg) (AmericanDiagnostica Inc, Greenwich, CT); trasylol (Bayer, Leverkusen,Germany); recombinant human amino terminal fragment (rhATF) of uPA was purified from LB6-Cl AF cellconditioned medium"; human plasma vitronectin (vn) and fibronectin (fn) were prepared as previously described," mouselaminin purified from the murine tumor EHS, was a kind gift from Dr G. Taraboletti (Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy), c-aminocaproic acid (cACA), paraformaldehyde, sucrose,tween-80(tw-80) (MERCK-Schuchardt, Darmstadt, Germany), crystal violet, fluorescein-tagged phalloidin from Amanita phalloides, bovineand human serum albumin (BSA and HSA), and Blood, Vol83, No 4 (February 15). 1994: pp 994-1005 PLASMINOGEN ACTIVATION ONECSURFACE a2-anti-plm (Sigma Chemical CO,St Louis, MO); diff-quik(Men Dade AG, Dudingen, Switzerland);mowiol4-88 (Hoechst, Frankfurt/Main, Germany); iodogen (Pierce Chemical CO,Rockford, IL); transwells tissue culture dishes (0.4-pmpore size, polycarbonate membrane filter)(Costar, Cambridge, MA); I4C-methylated protein molecular-weight standards (Mr200,000myosin,Mr 100,000 to 92,500 phosphorylase b, Mr 69,000 BSA, Mr 46,000 ovalbumin, Mr 30,000 carbonic anhydrase, Mr 14,3000 lysozyme) (Amersham International, Buckinghamshire, UK); phosphatidylinositol-specific phospholipase C fromBacilluscereus(PI-PLC) (Boehringer Mannheim GmbH, Mannheim, Germany); camerfree Na12’I (NewEnglandNuclearResearch Products, Boston, MA); and all culture reagents (GIBCO, Paisley, UK).All other reagents were ofthe highest chemical grade. Antibodies. Anti-P3subunit rabbit serum has been de~cribed,~’ antiplatelet EC-adhesion-molecule (PECAM) rabbit IgG36 was a kind gift from Dr P. Newman (Blood Research Institute, Milwaukee, WI), antihuman-fn rabbit serum was a kind gift from Dr G. Marguerie (Institut National de la Santi et de la Recherche Medicale, Grenoble Cedex, France), antimouse laminin rabbit serum was a kind gift from Dr G. Taraboletti (Istituto di RicercheFarmacologiche Mario Negri, Bergamo, Italy); anti-uPAR monoclonal antibody (MoAb) clone R4 (IgG) has been described3’; anti-intercellular adhesionmolecule-l (ICAM-I) MoAb (~upernatant)~~ was a kind gift fromDr N. H o g (Imperial Cancer ResearchFund, London, UK). Secondary antibodies used in immunofluorescence experiments were from Dakopatts (Glostrup, Denmark). Cell cultures. ECswere isolatedfrom normal-term umbilical cord veins by collagenase perfusionas previously de~cribed.’~ Cells were grown on tissue culture dishes coated with gelatin (0.5%)in 20% newborn calf-serum/Mvl99 medium supplemented with EC growth supplement (ECGS) (prepared from bovine brain) (50 pg/ mL), heparin ( 100 pg/mL), and penicillin (100 U/mL)/streptomycin (100pg/mL) (pen/strep) and used betweenthe first and the third passage. Human saphenous-vein ECs were kindly provided by Dr C. de Castellarnau (Fundacio d’lnvestigacioSant Pau, Barcelona, Spain). Cells were isolated from specimens of normal veins as previously described.34 Cells werecultured in M199,20% human serum supplemented with ECGS (50 pg/mL), heparin (100 pg/mL), and pen/ strep, on 0.5%gelatin coating and used at the fourth passage. Immunofluorescence. EC were plated on glass coverslips coated with 0.5% gelatin. They were incubated with the primary specific antibodies before or after being fixed. uPARstaining on living cells was previously describedby Pollanen et al.39Cells were fixed with ( 1 5 min3% paraformaldehyde in phosphate-buffered saline (PBS) utes at room temperature) containing 2% sucrose and washed three times with PBS. They were then incubated with the appropriated secondary antibody-fluorochromeand conjugated for 45 minutes at 37°C in PBS-I%BSA. After this step, some samples were permeabilized by incubating with0.5%Tx-100 in HEPESbuffer (20 mmol/L HEPES, 300mmol/L sucrose, 50mmol/L NaCI, 3 mmol/ L M&) for 4 minutes at 4°C. After extensive washing (three times with PBSand once with PBS-O.1% BSA), for double-labeling, samples were incubated with the second specificantibody followed by the second fluorochrome-conjugatedantirabbit or antimouse antibodies, which werediluted 1:40 in PBS- 1% BSA for 45 minutes at 37’C. Samples not permeabilized before were permeabilized now. Whencell-surface proteins had to be detected (such as uPAR, PECAM, or vn receptor) the permeabilization step was performed only at the end of the immunostaining protocol to avoid any nonspecific binding of the antibodies inside the cells. Inthe case of vinculin, cells were permeabilized beforethe addition of antivinculin antibodies. Labeling withor without permeabilizationwas compabe observed with permeabilrable, exceptthat a clearer image could ized cells. After extensive rinsing, coverslips mounted were in mow- + 995 io1 4-88. Routine observations were performedin a Zeiss Axiophot photomicroscope equipped for epifluorescence (Carl &is, Oberkochen, Germany) and fluorescent images were recorded on Kodak 400 films (Eastman-Kodak, Rochester, NY). Incubation with PIPLC (0.5 U/mL) was performed in serum-free M199for 1 hour at 37°C before cell incubation with anti-uPAR MoAbs. Light microscopy analysis of EC-monolayer retraction. ECs were grown to confluency in 96- or 24-well culture dishes coated with 0.5% gelatinand proteolytic treatment was performed on EC monolayers previously maintained in serum-free M199 (50 minutes at 37°C). Retraction was studied by the addition of plg in fresh serum-free M 199, followed after IO minutes by the addition of uPA. In some samples, ATF, tACA, and a,-anti-plm were also present and were added together with plg. Morphologic changes of the monolayer were observed at different times by light microscopy. Samples were photographed in a Zeiss IM 35 photomicroscope (Carl Zeiss) on Kodak plus-Xpan 125 films (Eastman-Kodak). In preliminary experiments,we partially definedthe composition of the extracellular EC matrix. ECs seeded on 0.5% gelatin-coated coverslips,were grown for7 days to reach the confluence in serumcontaining medium. By indirect-immunofluorescencemicroscopy using anti-fn and antilaminin antibodies, we found that a large amount of laminin and fn was present on the EC matrix after 7 days of culture (not shown). Proteoglycans have been previously described as a component of the EC matrix by Mertens et aLm Radioisotope labeling of proteins. plg and HSA were radioiodinated with camer-free Na12’I (7 to 1 1 pCi/pg ofprotein) using the Iodogen method for 15 minutes at room temperature according to the manufacturer’s procedure. The reaction was stopped by excess K1 and 1251-labeled proteins separated from free 1251 on a PD-IO column (Pharmacia LKB Biotechnology, Uppsala, Sweden). Specific activityof the proteins was 3 X IO6 cpm/pg for plg and IO6 cpm/pg for HSA.I2’I-HSAwas dialyzed before each experiment. 12SI-albuminendothelial permeabilityassay. To quantify the effect of the proteolytic treatment on EC-monolayer permeability we measured the passage of I2’I-HSAthrough EC confluent monolayersusing the Transwell system.4143Cellswereplated on fncoated polycarbonate filters (2 &well) placed on the upper compartment of the transwell chamber. After 7 days of culture, cells were kept for 50 minutes at 37°C in serum-free M199, which was then replaced with 100 pL serum-free M199 containing ”’I-HSA ( IO6 cpm) and 0.54 pmol/L plg in the upper compartment. In the lower compartment, 600 pLof serum-free M 199 waspresent. Proteolysis was started by the addition of uPA to the upper compartment as described above. In some experiments, ATF, cACA, a2anti-plm, and trasylol were presentduring the incubation and were added together withplg and I2’I-HSA. Atdifferent time points, 100p L samples were withdrawn from the lower compartment (replaced with serum-free M 199) and counted in a y counter. At the end of the experiment, monolayers on the filterswere diffquik fixed, crystal-violet stained, and photographed as described above.The discontinuities in ECmonolayer generatedby the plg-uPA treatment were quite different in number and size within replicates. However,the values of replicates ofuntreated monolayers were verysimilar. The inset of the figures shown with this kind of experiment have been added to partially overcomethis intrinsic problem. Statistical analysis. The Student’s t-test was used to determine if there were significant differences betweenexperimental groups. Samples fromat least three independent experimentswere grouped for this statistical analysis. Probability valuesof .05 were required for statistical significance. EC-mediated plg cleavage by uPA. ECs were grown to confluency in 96-well culture dishes coated with 0.5% gelatin. After serum-free M199 incubation (50 minutes 37’C), 0.8 pmol/L unlabeled plg containing ‘”I-plg ( I .5 X IO6 cpm/well) was added and 996 CONFORTI ET AL cells incubated for 10 minutes at 37'C. In some wells, after this inwhere it codistributed with PECAM (Fig 2, compare A with cubation, theradiolabeled plg mixture was substitutedwith 0.8 B). Nonimmune rabbit serum in double label with uPAR pmol/L unlabeled plg, corresponding to 200-fold molar excess of gave a negative staining (Fig 2D). When an anti-ICAM-l the cell-bound '2sI-plg,as calculated by counting in a y counter the MoAb was used as control, a bright diffuse staining of the unbound-radiolabeled plg, removed from the monolayer after 10 cell surface was observed with no specific localization of the minutes of incubation withcells. uPA (50 nmol/L) was then added antibody at cell-cell contacts (Fig 2F). Furthermore, suband cells incubated for a further I5 minutes at 37°C. At this time, confluent ECs also showed a more marked uPAR staining trasylol (800 KIU/mL) was added in the well, supernatants were at the cell border (Fig 2E), thus excluding a nonspecific acremovedandputinavessel containing electrophoresissample buffer for reduction and denaturation." Cell and extracellular ma- cumulation of the antibody caused by overlapping of neightrix extracts were preparedas d e ~ r i b e d . ~The ~ . ~cells ' were washed bor plasma membranes. Specificity of the anti-uPAR anti2 times withserum-free M199; then they were incubated for 10 body was shown by the lack of staining with nonimmune minutes at 20°C with PBS containing 0.5%Tx-100, trasylol (800 mouse IgG (Fig 2G), and by the sameuPAR antibody used KIU/mL), and 2.5%2-mercaptoethanol(2-ME)to remove thecells. on ECs treated with PI-PLC before immunostaining. As Wells were then washed once with serum-free M 199, and the reshown in Fig ZH,the majority of the staining was removed maining material (extracellular matrix) was removed with 60 pL of from the EC monolayer after PI-PLC treatment. tris-buffered saline (TBS) containing 1% sodium dodecyl sulphate Light microscopy analysis of plg-uPA-treated ECs. To (SDS), trasylol (800 KIU/mL) and 2.5% 2-ME. Sample were then mixed with denaturing and reducing electrophoresis sample buffer.study the effect of plm formation on theintegrity of the EC In some experiments, cACA was present during the incubation and monolayer, we treated these cells with plg and uPA. This type of study is made difficult by the high concentration of was added together with plg. Radioactivity was measured in a y counter, samples fractionated in SDS-polyacrylamide gel electroPAL 1 produced by ECsin vitro. To obtain a detectable cellphoresis (PAGE) (10%acrylamide)and dried gels autoradiographed surface activity, concentrations over 40 nmol/L uPA and at -70°C. The autoradiogramswere scanned and quantitated using over 0.3 pmol/L plg are required.16 In preliminary experia computerized image analysis system (RAS 3000; Loats System, ments in which a plg dose-response curve was tested (range Wemnister, MD). 0.54 to 1 pmol/L), we have determined that a morphologic RESULTS Immunofluorescence analysis of EC monolayers. We first investigated the presence and localization of theuPAR by immunofluorescence analysis using specific anti-uPAR MoAb." Confluent ECs seeded on gelatin-coated coverslips were stained with anti-uPAR and antivinculin antibodies. The primary anti-uPAR antibody and the rhodamine-labeled rabbit-antimouse IgG were given before cell permeabilization. Only after thisstep, cells weredetergent permeabilized, incubated with antivinculin antibody followed by fluorescein-labeled goat-antimouse IgG. uPAR was found in distinct patches reminiscent of the focal contacts (Fig 1, A and C). Thisis confirmed by the uPAR codistribution with vinculin (Fig 1, B and D), similar to what was previously observed in a human fibrosarcoma cell line and in human fibroblast~.'~*~~*~' lack The of colocalization of some vinculin strands (Fig 1, small arrows), indicates specificity ofthe double staining. Codistribution with vn-receptor also shows the presence of uPAR in focal contacts (Fig 1, E and F). Here the doublelabeling was performed using anti-uPAR MoAb and anti83 rabbit serum. When the anti-fi3 rabbit serum was substituted by nonimmune rabbit serum in double label with uPAR, no focal contact strands were present (Fig 1, G and H). Confluent cells were also analyzed by doubleimmunofluorescence labeling for uPAR and PECAM. PECAM can be considered a specific marker of endothelial cell-cell contact sites.48 In thiskind of experiment,the primary anti-uPAR MoAb was added to living ECs. After fixation, cells were incubated with fluorescein-labeled goatantimouse IgGfollowed by the addition of rabbitantiPECAM IgG and then rhodamine-labeled swine-antirabbit IgG; finally, cells were detergent permeabilized (see Materials and Methods). uPAR was found both at focal (small arrows) and cell-cell contact sites (Fig 2 , A and C, large arrows) effect of plg-uPA treatment was visible at 0.8 rmol/L plg and 50 nmol/L uPA (not shown). Addition of plg and uPA to confluent EC generated a loss of the monolayer integrity as shown by light microscopy analysis of 90-minute-treated cells, whereas the untreated EC monolayer incubated in serum-free medium was unchanged (Fig 3, compare A with B). This effect increases very slowly and after 6 hours the monolayer forms lacunar-like structures (not shown) that appear because of retraction of the cells. The effect is fully reversible by substitution of plg-uPA-containing medium with fresh medium containing serum after 90 minutes (Fig 6 hours (not shown) of treatment. In addi3C), such as after tion, at 90 minutes, counting of the nuclei at the light microscope did not show any difference between treated and untreated cells. However, after 6 hours of plg-uPA treatment, the nuclei number decreased by 20% to 40%. This is probably caused by detachment of cells occurring at late times. The detached cells were 50% dead, by trypan blue staining. In some experiments, ECs were plated on gelatin, fn, vn, and laminin and grown to confluence over a period of 7 days in serum-containing medium. After plg-uPA treatment of the monolayer, cell retraction occurred independently of the coating protein they had been seeded on (data not shown), suggesting that this phenomenon was not influenced by the coating protein on which the ECs were plated and grown for a week in serum-containing medium. In Table 1 are shown the data comparing the activity of different PAS in inducing EC retraction. When EC monolayers were treated with pro-uPA instead of uPA, the prouPA was 50-fold more active than uPA on thegeneration of EC retraction. This finding suggests that a large fraction of the added uPA was neutralyzed by the PAL1 located beneath the EC monolayer on the cell matrix, as previously reported by Barnathan et t-PA (50 nmol/L) was also able to induce EC retraction. PLASMINOGEN ACTIVATION ON EC SURFACE 997 Fig 1. Double-immunofluorescencelabeling of uPAR and vinculin or vnreceptor. Cells were fixed and incubated (A and C) with R4. anti37'C. followed by rhodamine-conjugatedrabbit-antimouse lgG, then they were penneabilized(see uPAR MoAb ( 5 pg/mL) for 3 0 minutes at Materials and Methods). For double labeling, these same cells were incubated (B and D) with MoAb antivinculin for 3 0 minutes at 37'C. followed by fluorescein-conjugated goat-antimouse IgG. Two representative fields are shown from specimens of two independent experiments. Other EC samples were incubated with anti-O3 (F) or nonimmune rabbit sera (H) (diluted 1 :l 00) for 30 minutes at 37'C. then, for double labeling, they were bothincubated (E and G) with R4, anti-uPAR MoAb ( 5 pg/mL) for 20 minutes at 4'C before cell fixation. Cells were then washed, fixed, and incubated, first with fluorescein-conjugated goat-antimouse IgG, to detect the uPAR, then with rhodamineconjugated swine-antirabbit IgG to detect the B3 subunit of the vnreceptor. Finally they were permeabilized(see Materials and Methods). Small arrows indicate where uPAR and vinculin in focal contacts are shifted, large arrows where they codistributed. Bar, 20 pm. 998 CONFORTI ET AL Fig 2 . Double-immunofluorescencelabeling of uPAR and PECAM. ECs plated on gelatin-coated coverslips were grown to confluency. The cells were incubated (A, C, E, and H) with R4, anti-uPAR MoAb ( 5 pg/mL). The cells shown in H were treated with PI-PLC (0.5 U/mL). before the addition of the uPAR antibody. Control cells were incubated (F) with MoAb anti-ICAM-l (diluted 1: 5 ) and (G) with nonimmune mouse lgG (5 pg/mL). All primary antibodies were added to the cells at 37'C for 30 minutes before cell fixation. Cells were fixed then incubated with fluorescein-conjugated goat-antimouse IgG (A,C, E, and G) and with rhodamine-conjugatedrabbit antimouse IgG (H and F). For double labeling, some of the samples previously labeled for uPAR were incubated with anti-PECAM-rabbit IgG (2.5 rg/mL) (B). nonimmune rabbit IgG (2.5 pg/mL) (D) for 30 minutes at 37°C. followed by rhodamine-conjugated swine-antirabbit IgG. Finally, all the samples were detergent permeabilized(see Materials and Methods). The ECs shown in (E) were used at subconfluency. Small arrows indicate focal contacts, large arrows indicate cell borders. Bar, 2 0 pm. PLASMINOGENACTIVATIONON 999 EC SURFACE Treated Untreated EC monolayers grown in 24-well plates were mainFig 3. plg-uPA treatment induces changes of EC-monolayer morphology. Confluent tained in serum-free M199 for 50 minutes, then treatedwith plg (0.8pmol/L) anduPA (50 nmol/L) as described in Materials and Methods. (A) plg-uPA treated cells; (B) the corresponding untreated control maintainedin serum-free medium. Photographs of the monolayers were taken after 90 minutes from the addition ofuPA, on living cells. Two representative fields of plg-uPA-treated cells are shown. (C) The 1 hour after removal of plg-uPA medium and recovery ofEC-monolayer integrity, after 90 minutes of plg-uPA. The photograph was taken cells.80 pm. substitution with fresh M199 containing serum. Arrows indicate sites of discontinuity between Bar, However, considering the specific biologic activity of the two proteins used, tPA (792,000 to 704,225 IU/mL) versus uPA (100,000 IU/mL), we have calculated that uPA was at least IO-fold more efficient in inducing EC retraction. Interestingly, when we used the low molecular-weight uPA (33 Table 1. Comparison of Different PAS in Inducing €C Retraction PAS nmol/L IU/Well uPA 15 pro-uPA tPA Low molecular weight uPA 50 1 50 100 144-161" 32 - Confluent EC monolayersin 96-wellculture dishes were proteolitically treated as described in Materials and Methods. Retraction was studied by the addition of plg in serum-free medium, followed after 10 minutes by the addition of the PAS(reactionvolume = 6 0 pL). The concentration range tested for each PA was 0.1 t o 100 nmol/L. The table reports the minimal dosefor each PA ablet o induce cell retraction at the same time and at a degree comparablewith 5 0 nmol/L uPA, consideredthe positive control. The comparison began when cellstreated with 50 nmol/L uPA started to retract. Cells were observed every 15 minutes for 1 hour. At the last time, they were fixed and stained (see Materials and Methods). Samples were run in duplicate, in two independent experiments with comparable results. Two batches of tPA were used for each experiment. kD), in which the uPAR binding site is missing, a twofold amount was required to obtain the EC retraction effect observed with the 50 kD uPA. Plasmin itself (0.8 pmol/L) could induce EC retraction when added to EC monolayer. The cell retraction we have found with ECs was also observed when human saphenous ECs were used, suggesting that this is not a specific property of ECs,but that it is common to the endothelium from different vascular districts. Duplicate samples were run in two independent experiments giving the same results (data notshown). Quantitation of EC-monolayer retraction by measure of monolayer permeability. Toquantitate the loss ofEC monolayer integrity, we measured the permeability to '251HSA using a Transwell permeability system. Confluent ECs, grown on fibronectin-coated filters in the upper compartment of the transwell chamber, were plg-uPAtreated in serum-free medium supplemented with I2'I-HSA (see Materials and Methods). At different times, samples were withdrawn from the lower compartment and theradioactivity, passed from the upper to the lower compartment, counted. plg-uPA treatment increased EC-monolayer permeability starting within 20 to 70 minutes from the addition of uPA to the monolayer, whereas the single components had no effect (Fig 4A). The effect was dependent on uPA concentration (Fig 4B). For each point of the kinetic and CONFORTI ET AL "1 A plg-uPA treatment itself did not modify the fn-coated filter permeability. In fact, in the absence of cells the permeability of I2%HSA wassimilar for the untreated or plg-uPAtreated fn-coated filters. Nor was 1251-HSAdigested during the time of incubation, asassessed bySDS-PAGE and autoradiographic analysis of I2'I-HSA samples collected at different times (data not shown). Cell-surfaceboundplm is involved in the loss ofEC-monolayer integrity by plg-uPA. Several data have shown that surface-bound plrnis resistant to a2-anti-plm, as lysinebinding sites are required for both cell-surface and az-antiplm Trasylol, on the other hand, does not discriminate between soluble and lysine binding site-bound 0 60 80 100 120 140 160 plm. Figure 5 shows a typical experiment in which the increased EC permeability caused by the plg-uPA treatment Time (min) could be 60% inhibited by a2-anti-plm at 150 minutes but was fully inhibited by trasylol. At 90 and 120 minutes, the plg-uPA-treated samples compared in the presence and ab15 sence of trasylol gave P values of .05 and .03, respectively. The inset of the figure shows ECs grown on filters, fixed, and stained at the end of the experiment (after 150 minutes of plg-uPA treatment). cY2-anti-plm could only partially pro10 tect the monolayer by plg-uPA treatment compared with trasylol. On the other hand, both a2-anti-plm and trasylolinhibited plm in solution over 90% as measured on super5 natant samples taken at the end ofthe experiment and tested by a chromogenic substrateassay (S225 1) (data not shown). In three independent experiments, the average inhibition by 0 k 7 SE at 150 minutes with a P value of cyanti-plm was 64 0 20 40 60 80 100 .07. Thus, surface-bound plrn may be involved in theloss of [uPA] nM EC-monolayer integrity. A role for lysine binding sites in the loss of cell-cell conFig 4. Quantitative analysis of the time and uPA concentrationtacts was also supported by additional light-microscopy data (A) TimedependentgenerationofEC-monolayerpermeability. in which plg-uPA treatment was performed in the presence course. (Cl) plg-uPA treated cells; (m) treated cells with uPA alone; or (0)with plg alone. (B) uPA dose-response. The cellswere mainof 5 mmol/L tACA, which competes with the cell surface tained in serum-free medium for 50 minutes beforethe addition of for plg binding. As shown in Fig 6, incubation of cells with the same amountof plg (0.54rmol/L) followed after 10 minutes by plg in the presence of 5 mmol/L cACA followed by the adincreasing amountsof uPA. At the indicated time (A) and after 120 dition of uPA, strongly decreased the effect of the plg-uPA minutes (B) from the addition of uPA, l00 #L of samples (of 600 treatment (compare C with B). In this experiment, a conpL) were withdrawn from the lower compartment of the transwell chamber and counted in ay counter (see Materials and Methods). centration of 100 nmol/L uPA was used to obtain a strong exEach point(A and B) is the mean of duplicates from one typical effect and to better visualize the inhibition.Combining periment. The background radioactivity of untreated cells, maintACA and a2-anti-plm resulted in a further reduction of the tained in serum-free medium, has been subtracted from each curve. plg-uPA effect, although the inhibition was still not comthan 10%and Duplicates of plg-uPA-treated samples diRer by less plete (Fig 6, D). In the Transwell system under the same of untreatedsamples by less than 5%. experimental conditions, tACA inhibited by 53% the plguPA-induced permeability (not shown).Data of'"I-plg dose-response curves, the standard error calculated on the cleavage by uPA in the presence of tACA also strongly indimean of two independent experimentsrun in duplicatewas cate that cell surface plays an important role in the modifiless than 10%. cation of the EC monolayer caused by plg activation (see In some experiments, the passage ofI2%HSA through the below). fn-coated filters, in the presence or absence of cells, was Functional role of receptor-bound uPA in the loss of ECmeasured. Fn-coated filters were incubated with or without monolayer integrity. Activation of plg byendogenous uPA cells in 20% NCS-containing M 199 medium for 1 week, unis totally dependent on the cell surface.13 To directly test til cells reached the confluence. Then cells or filters were plgwhether exogenously added receptor-bound uPAwas inuPA-treated and the passage of "'I-HSA measured. In the volved in EC retraction, the enzymatically inactive ATF of absence of cells, the passage of "'I-HSA through the filters uPA, which competes with uPA for bindingto receptor, was was faster; within the first 10 minutes, we measured IO-fold used as an antagonist of the plg-uPA effect on EC. In the more '251-HSAin the lower compartment of the transwell monolayer permeability assay, ATF inhibited plg-uPA-inchamber compared to filters with cells. At 120 minutes, duced HSA permeability by 66% at 90minutes as shown in when the EC monolayer was retracted, a fivefold difference a typical experiment (Fig 7). The average inhibition by ATF was observed. "1 B 1001 PLASMINOGEN ACTIVATIONON EC SURFACE H X E + a2-antiplasmin 0 + trasylol 8- Q S a U) 6- I v) cu 7 4- LC 0 2- 0 0 20 40 60 80 100 Time (min) 120 140 160 Fig 5. Effect of protease inhibitors on EC-monolayerpermeability. Confluent EC monolayers grown on fibronectin-coated transwell filters were incubated with 0.54 pmol/L plg in presence of lZ51-HSA(1Og cpm/well). After 10 minutes 50 nmol/L uPA was added. ( 0 )No inhibitors; (m) n,-anti-plm; (0)trasylol. Both inhibitors were used at a molar concentration (1.62 pmol/L) threefold excess over plg. EC-monolayer Permeability was measured at different times counting the lz5l-HSAcontained in 100 pL of samples (out of 600 pL) withdrawn from the lower compartment of the transwell chamber. Each point represents the mean of duplicates. The background radioactivity of untreated cells, maintained in serum-free medium, has been subtracted from each curve. Duplicate of plg-uPA-treated samples in the presence or absence ofaianti-plrn differ by lessthan 10%. Untreated samples or plg-uPA-treated samples in thepresence of trasylol differ by lessthan 5%. Inset shows EC monolayers at theend of the experiment (1 50 minutes of plg-uPA treatment). Photographs were taken on cells fixed with diff-quik and stained with crystal-violet. Bar, 100 pm. in four independent experiments was 46% k 9% SE at 90 minutes with a P value of .07. ATF added to theuntreated EC did not modify EC monolayerpermeability (not shown). Light microscopic assessment of EC morphology was performed in parallel dishes. Figure 7, inset, shows that after 90 minutes of EC treatment with plg-uPA, ATF could almost entirely prevent morphologic changes (A v C). However, the inhibitory effect of ATF was transient because visible ECmonolayer damage became apparent at 150 minutes (B v D). The addition of cu2-anti-plm,which inhibits plmactivity in solution together with ATF, which inhibits cell-surface plm generation, raised the percentage of inhibition up to 75% at l50 minutes (not shown). These data show that cellsurface binding of uPA is an important prerequisite in plguPA-induced EC retraction. Plg is uctivuted on EC surface. To test whether plg activation took place on thecell surface under our experimental conditions, we incubated ECs with a plg concentration able to generate EC-monolayer retraction, 0.8 pmol/L, but also containing 1.5 X lo6cpm 1251-plg.After 10 minutes, the radiolabeled mixture was removed and cell-bound IZ5I-plg chased by the addition of 0.8 pmol/L unlabeled plg (corresponding to 200-fold molar excess ofthe cell-bound I2%plg, see Materials and Methods), .then incubated for further 15 minutes at 37"C, in the presence of 50 nmol/L uPA. Supernatants were then removed, and cell and matrix extracts prepared as described under Materials and Methods. Samples were analyzed by SDS-PAGE under reducing conditions and autoradiography. As shown in Fig 8A, plm was generated in the presence of uPA with bands at about 72 CONFORTI ET AL 1002 untreated + EACA plg-uPA treated + E ACN% -antiplasmin Fig 6. Role of lysinebinding sites in cell-associated proteolysis.€C were grown at confluency on 0.5% gelatin-coated microtiter wells and treated with plg-uPAin serum-free medium as describedin the legend to Fig 3. (A) Untreated €C moodayer; (B) plg-uPA-treated cells. In (C) and (D),cells were incubated, respectively, with 5 mmol/L tACA or 5 mmol/L rACA plus 2.4 pmol/L a,-anti-plm, which were added alongwith 0.8 pmol/L plg, 10 minutesbeforeadditionof uPA (100 nmol/L). Photographs were taken after 2 hours of treatment on fixed and stained cells (see legend to Fig 5). Bar, 100 Mm. and 27 kD in the supernatant (lane l), in the cell-associated agreement with previous data." Interestingly, in our experfraction (lane 2), and in the matrix-associated fraction(lane imental system, thesedata show that in presence of cACA, 3). By far, the highest efficiency of plrnformation was in the when most of the plrn is present in the phase solution, EC cell-associated fraction. Interestingly, when unbound "'lretraction was strongly inhibited (Fig 6C), suggesting again the importance of cell-associated plrn in the generation of labeled plg was not chased with the unlabeled competitor plg (Fig 88). the cell-surface preference for plrn formation this phenomenon. disappeared (lanes 4 to 6). By 'zsI-plgcleavage assay,we calDISCUSSION culated that 92%of cell-associated plg was activatedby 50 nmol/L uPA within I5 minutes. This value was determined In this report, we have shown that uPAR in EC is localby densitometric scanningof the autoradiogram measuring ized at cell substratum aswell as at cell-cell contacts (Figs1 the intensity of the bands correspondingto the high and low and 2). In focal contacts, uPAR colocalized with uPA (data molecular-weight plrn chains or to the uncleaved plg, after not shown), vinculin, and vn receptor. The colocalization samples fractionation in SDS-PAGE and autoradiography of uPAR with vn receptor has alsobeen found for human (Fig SB, lane 5 ) . As also shown previously by other investirhabdomyosarcoma cells, embryonic skin fibroblast, and gators, bound Izsl-plg partially dissociated from cell bindingadherent U937 cell^.^' uPAR codistributed with PECAM at sites49; however,the presence of excess unlabeled competicell-cell contacts, suggesting that the two molecules are astor plg (Fig SA) rules out the possibility that 12SI-plmwas sociated to similar junctional structures. Wehave also formed in solution from the released 12sI-plgand subseshown that treatment of EC with plg-uPA generates morquently rebound to the cells. Therefore, we conclude that phologic and functional changes of EC monolayer (Fig 3) under our experimental conditions, plrn formation takes with a retraction accompaniedby an increasein monolayer place onthe cell membrane. permeability to high molecular-weightsolubleproteins IzsI-plg cleavage by uPAin presence of 5 mmol/L cACA (HSA). The EC-retraction phenomenon was not influenced by inhibited the interaction ofplg with the EC by 85%.Furthermore, in the presence of tACAthe plg was 100%converted the coating protein on which the cells were plated (fn, vn, to plrn in cell, matrix, and fluid-phase-associated fractions laminin, or gelatin). This is not surprisingbecause, in such (not shown), whereasin the absence of cACA some plg reexperiments, although the cellswereplatedondifferent mained partially uncleaved. under the same experimental coating proteins, they were then cultured for several days conditions(Fig S, lanes 4 through 6). These results highlight in serum-containing medium before the plg-uPA treatment. two important points: first, that the inhibition mechanism We believe that during the time ofcell culture, they produce of EC retraction by tACA may be at least in part, related to and secrete their own extracellular matrix proteins; proteins from serum can also be adsorbedon the initial coating,both the inhibition of the plg-binding to the cells: second, that tACA-boundplgismoreefficientlyactivated to plm, in contributing in making the final matrix quite similar. Our PLASMINOGENACTIVATIONON EC SURFACE 1003 90 min Fig 7 . Effect of ATF on ECmonolayer permeability. EC were grown to confluency on fibronectin-coated transwell filters (see Materials and Methods). Cells were plg-uPA treated in serum-free medium as described in legend to Fig 3. ATF (1.2 pmol/L) was added together with plg (0.54 pmol/L), 10 minutes before the addition of uPA (50 nmol/L). (Bottom) (0) plg-uPA-treatedcells; (0) plguPA-treated cells in presence of ATF. At different times, 100 pL of samples were counted in a y wunter (seelegend to Fig 5). Each point represents the mean of duplicates which differ by less than 10%.Thebackgroundradioactivity of untreated cells, maintained in serum-free medium, has been subtracted from of uneachcurve.Duplicate treated cells differ by less than 5%. (Top) Morphologic analysis of cells performed in parallel, and pictures taken on fixed and stainedcells at the indicated time. Bar, 100 pm. data, in which laminin and fn were found on cellscultured on gelatin,support this hypothesis (data not shown). The retraction effectiscausedbyplrn formation, as shown by the inhibition by trasylol and a2-anti-plm. However,whereastrasylolcouldtotallyinhibit the plg-uPA effect, n2-anti-plmwas only partially inhibitory, indicating that a quota of plrn is generated at the cell surface. In fact, surface-bound plrn is protected from the a2-anti-plm action, but not fromtra~ylol.~~." Moreover, tACA.a molecule that prevents plg binding to the cell surface by competing with cells forplg lysine-binding sites" could also inhibit the effect of plg-uPAtreatment. Preferential activation of plgon the cell surface was also shown by direct experiments (Fig 8). The plrn formation oncell surface depends on the binding of uPA to uPAR becausethe uPAR antagonist, ATF, inhibited both functional and morphologic effects. The effect of plg-uPA on EC is not accompanied by an indiscriminate 150 min 40 60 Time (min) 80 100 proteolysis of cell-cell and focal-contact molecules.In fact, immunofluorescence experiments failed to show any major changes in the distribution of uPAR, vn receptor, and PECAM (data not shown). The fact that tPA could alsoinduce EC retraction was not surprising, because t-PA has beenshownpreviously to activate cell-bound plg more efficiently than fluid-phase pig." Moreover, receptors fortPA have been identified on ECS.'~However, the plg-activation efficiency of the tPA was IO-fold lower than the uPA, and it was much lower if compared with the pro-uPA. A possible explanation for this canbe the intrinsic characteristic ofthe tPA that requires fibrin as cofactor to efficiently induce plg activation. Because receptor for plg can also bind plm," the EC retraction induced by the addition of plrn itself strongly indicates that this isa plm-mediated event.In the case ofthe low molecular-weight uPA, plrn formation in fluid phase could also be the cause of EC retraction. We believe that some of 1004 - CONFORTI ET AL A The morphologicandfunctionaleffectsare wellexplained by the localization ofuPA and uPAR, as EC retraction and monolayerpermeabilitymay be logicalconsequences of proteolyticeventsoccurring at cell-cell and cell-substratum contacts. uPA and uPAR have been shown to be essential in the dissemination of tumor cells in a variety of modelsystem~.~"'The findings reported in this report open the way to a molecular studyof the role of the cell-surface plg activation in extravasation. ACKNOWLEDGMENT We thank Dr J.Henkin for providing ATF. REFERENCES t 1 2 3 4 5 6 7 8 Fig 8. Effect of ECson plasminogencleavage by uPA. Confluent €C monolayers in microtiter wells were maintained in serum-free medium for 50 minutes. Cells were thenincubated with fresh medium containing '*'I-plg (1.5 X loE cpm/0.8 pmol/L) which was substituted (A) or not (B)after 10 minutes with unlabeled plg (0.8 pmol/L). At this time, uPA (50nmol/L) was added to all samples and the incubation was continued for another 15 minutes. Lanes 1 and 4, supernatants; lanes 2 and 5,cell extracts; lanes 3 and 6, matrix extracts; lane 7, '%-molecular-weight markers; lane 8, '2sI-plg (starting material). Arrowheads point to the formed high and low molecular-weight plrn chains. Note that a t longer film exposure, low molecular weight plrn was also evident in (A) (lanes 1, 2, 3). Only 8% (lane 1) and 1.2% (lane 4) of the supernatant were loaded onto the gel, whereas the whole cell and matrix extracts were used in lanes 2,3,5, and 6. I . Nicolson CL: Cancer metastasis: Tumor cell and host organ properties important in metastasis to specific secondary sites. Biochim Biophys Acta 948: 175. 1988 2. Blasi F: Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness. BioEssay 15:105. 1993 3. Ossowski L, Reich E: Changes in malignant phenotype of a human carcinoma conditioned by growth environment. Cell 33: 323. 1983 4. Hearing VJ. Law LW. Corti A. Appella E. Blasi F Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 48: 1270. I988 5. Ossowski L. Rum-Payne H, Wilson E L Inhibition of urokinase-type plasminogen activator by antibodies: The effect on dissemi- nationofahumantumorinthenudemouse.CancerRes51:274,1991 6. Ossowski L. Clunie G. Masucci MT. Blasi F:In vivo paracrine interaction between urokinase and its receptor: Effect on tumor cell invasion. J Cell Biol I 15: I 107. l99 I 7. Quax PHA. Pedersen N. Masucci MT. Weening-Verhoeff EJD, Dana K. Verheijen JH, Blasi F: Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation. Cell Regul2:793. 1991 8. Mignatti P. Robbins E, Rifkin DB: Tumor invasion through the human amnioticmembrane: Requirement for a proteinase cascade. Cell 47:487. 1986 9. Cajot JF. Schleuning WD. Medcalf RL, Bamat J. Testuz J, Liebermann L. Sordat B Mouse L cells expressing human prourokinase-type plasminogen activator: Effects on extracellular matrix the plrn that is formed in solution can bind to the cell surdegradation and invasion. J Cell Biol 109:915. 1989 face, because a continuous equilibrium is established beIO. Cajot JF, Bamat J, Bergonzelli GE. Kruithof EKO, Medcalf tween free and bound plg/plm. However, because soluble RL. Testuz J, Sordat B: Plasminogen-activator inhibitor type I is plrn is readily blockedin vivo by physiologic plrninhibitors, a potent natural inhibitor of extracellular matrix degradation by its activation onthe cell surface by receptor-bound uPA or fibrosarcoma and colon carcinoma cells. Proc Natl Acad Sci USA tPA remains an important step for the cell-associated plrn 87:6939, I990 formation. I I . Hart PH. Vitti CF. Burgess DR. Whitty CA, Royston K, The inhibitory effect obtained with compounds that can Hamilton JA: Activation of human monocytes by granulocyteprevent cell-surface plg activation (cACA and ATF) is only macrophage colony-stimulating factor: Increased urokinase-type plasminogen activator activity. Blood 77:84 I . 199 I partial, indicatingthat active plrn may leak to the medium. 12. Blasi F. Vassalli JD, Dan0 K: Urokinase-type plasminogen acbeThis may beevident in the present experimental system, tivator: Proenzyme, receptor, and inhibitors. J Cell Biol 104:801,1987 cause of thehigh concentration of uPA and plg that need to 13. Stephens RW. Pollanen J, Tapiovaara H, h u n g K CSim , P-S, be added. Moreover,in vitro culturedECs represent a closed Salonen E-M, Renne E. Behrendt N, Dana K, Vaheri A: Activation system wherecellular secretions and added reagents remain ofpro-urokinase and plasminogen on humansarcoma cells: A proteounperturbed. However, in vivo, the ECs are under a conlytic system withsurface-bound reactants. J Cell Biol 108:1987, 1989 stant flow, where solublecomponents are removedand pro14. Roldan AL. Cubellis MV, Masucci MT. Behrendt N, Lund teases may be inactivatedby the presence of circulatinginLR, Dana K, Appella E, Blasi F Cloning and expression of the rehibitors. Our data strongly indicatethat an important quota ceptor for human urokinase plasminogen activator, a central moleof effective plgactivation does indeedtake place at the cell cule in cell surface. plasmin dependent proteolysis. EMBO J 9:467. I990 surface. PLASMINOGEN ACTIVATION ON ECSURFACE 15. Barnathan ES, Kuo A, Kariko K, Rosenfeld L, Murray SC, Behrendt N, Rsnne E, Weiner D, Henkin J, Cines D B Characterization of human endothelial cell urokinase-type plasminogenactivator receptor protein and messenger RNA. Blood 76: 1795, 1990 16. Barnathan ES, Kuo A, Rosenfeld L, Kariko K, Leski M, Robbiati F, Nolli ML, Henkin J, Cines DB: Interaction of singlechain urokinase-type plasminogenactivator with human endothelial cells.J Biol Chem 265:2865, 1990 17. Hajjar KA, Harpel PC, Jaffe EA, Nachman R L Binding of plasminogen to cultured human endothelial cells. J Biol Chem 26 I: 11656, l986 18. Miles LA, LevinEG, Plescia J, Collen D, Plow E F Plasminogen receptors, urokinase receptors, and their modulation on human endothelialcells. Blood 72:628, 1988 19. Blasi F Surface receptorsfor urokinase plasminogen activators. Fibrinolysis2:73, 1988 20. Behrendt N, PlougM, Patthy L, Houen G, Blasi F, Dan0 K The ligand-binding domain of the cell surface receptor for urokinase-type plasminogenactivator. J Biol Chem 266:7842,1991 2 l . Ploug M,Rmne E, Behrendt N,Jensen AL, Blasi F,Dan0 K Cellular receptor for urokinase plasminogen activator. Carboxylterminal processing and membrane anchoring by glycosyl-phosphatydylinositol. J Biol Chem 266: 1926, 1991 22. Cubellis MV, Nolli ML, CassaniG, Blasi F Binding of single-chain prourokinase to the urokinase receptor of human U937 cells. J BiolChem 261:15819, 1986 23. Appella E,Robinson EA, Ullrich SJ, Stoppelli MP, Corti A, Cassani G, Blasi F: The receptor-bindingsequence of urokinase. A biological function for the growth-factor module of proteases. J Biol Chem 262:4437, 1987 24. Stoppelli MP,Corti A, SoffientiniA, Cassani G, Blasi F, Assoian RK: Differentiation-enhancedbinding ofthe amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA 82:4939, 1985 25. Ellis V, Scully MF, Kakkar VV: Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem 264:2185, 1989 26. Manchanda N, Schwartz BS: Single chain urokinase. Augmentation of enzymatic activity uponbinding to monocytes. J Biol Chem 266:14580,1991 27. Plow EF, Freaney DE, PlesciaJ, Miles LA: The plasminogen system and cell surfaces: Evidencefor plasminogen and urokinase receptors on the same cell type.J Cell Biol 103:24I I , 1986 28. Ellis V, Behrendt N,Dan0 K Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated 1 and isolated receptor.J Biol Chem 266: 12752, 199 29. Blasi F, Verde P: Urokinasedependent cell surface proteolysis and cancer. Semin Cancer Biol l :I 17, 1990 30. Stoppelli MP, Tacchetti C, Cubellis MV, Corti A, Hearing VJ, CassaniG, Appella E, Blasi F Autocrine saturation of pro-urokinase receptorson human A43 1 cells. Cell 45:675, 1986 matrix of 3 I . Mimuro J, Schleef RR, Loskutoff DJ: Extracellular cultured bovine aortic endothelial cells contains functionallyactive type I plasminogen activator inhibitor. Blood 70:72 I, 1987 32. Preissner KT, Grulich-Henn J, Ehrlich HJ, Declerck P, Justus C, Collen D, Pannekoek H, Muller-BerghausG: Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associatedvitronectin. J Biol Chem 265: 18490, 1990 33. Pedersen N, Masucci MT,Mdler LB, Blasi F A noncatalytic, by human urokinase plasminogenactivatorderivativeproduced 5: 155, 199I mouse cells has full receptor binding activity. Fibrinolysis 34. Conforti G, Dominguez-Jimenez C, Zanetti A, Gimbrone MA Jr, Cremona 0, Marchisio PC, Dejana E Human endothelial 1005 cells express integrin receptors on the luminal aspect of their membrane. Blood 8 0 1, 1992 35. Conforti G, Zanetti A, Pasquali-RonchettiI, Quaglino D Jr, Neyroz P,Dejana E Modulation of vitronectin receptor binding by membrane lipid composition. J Biol Chem 265:W1 1, 1990 36. Newman PJ, Hillery CA, AlbrechtR, Parise LV, Berndt MC, Mazurov AV, Dunlop LC, Zhang J, Rittenhouse SE Activationdependent changes inhuman platelet PECAM-1: Phosphorylation, cytoskeletal association, and surface membrane redistribution. J Cell Biol I 19:239, 1992 37. Rmne E, Behrendt N, Ellis V, Ploug M, Dan0 K,Hayer-Hansen G Cell-induced potentiationofthe plasminogen activation system is abolishedby a monoclonal antibody that recognizesthe NH,terminal domainofthe urokinase receptor. FEBS Lett 288:233,1991 38. Dransfield I, Cabanas C, Barrett J, H o g N: Interaction of leukocyte integrins with ligand is necessary but not sufficient for function. J Cell Biol 1 16: 1527, 1992 39. Pollanen J, Saksela 0,Salonen E-J, Andreasen P, Nielsen L, Dan0 K, Vaheri A: Distinct localizations of urokinase-type plasminogen activator and its type l inhibitor under cultured human fibroblastsand sarcoma cells. J Cell Biol 104:1085, 1987 40. Mertens G, Cassiman J-J, Van den Berghe H, Vermylen J, David G: Cell surface heparan sulfate proteoglycans from human vascular endothelial cells. Core protein characterization and antithrombin I11 binding properties. J Biol Chem 267:20435, 1992 41. Langeler EG, Sneltin-HavingaI, van Hinsbergh VWM: Passage of low density lipoproteins through monolayers of human arin in vitro terial endothelialcells. Effectsof vasoactive substances an model. Arteriosclerosis9550, 1989 42.Lynch JJ, Ferro TJ, BlumenstockFA,BrockenauerAM, Malik AB: Increased endothelialalbumin permeability mediatedby protein kinaseC activation. J Clin Invest 85: 199 I , 1990 43. Lampugnani MC, Resnati M, Dejana E, Marchisio PC The role of integrins in the maintenance of endothelial monolayer integrity. J Cell Biol 1 I2:479, 1991 44. Laemmli U K Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680, 1970 45. Ehrlich HJ, Klein Gebbing R, Preissner KT, Keijer J, Esmon NL, Mertens K, Pannekoek H: Thrombin neutralizes plasminogen activator inhibitor I (PAI-I) that is complexed with vitronectin in the endothelial cell matrix. J Cell Biol I 15: 1773, 199I 46. Pollanen J, Hedman K, Nielsen LS, Dan6 K, Vaheri A: Ultrastructural localizationof plasma membrane-associated urokinase-type plasminogen activatorat focal contacts.J Cell Biol 106:87, 1988 47. Hkbert CA, Baker JB: Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: Colocalizationof cell surface urokinase with vinculin.J Cell Biol 106: 1241, 1988 48. Albelda SM, Muller WA, Buck CA, Newman PJ: Molecular and cellular properties of PECAM- I (endoCAM/CD31): A novel vascular cell-cell adhesion molecule. J Cell Biol I 14: 1059, 1991 49. Humphries JE, Vasudevan J, Gonias SL: Fibrinogenolytic andfibrinolyticactivity of cell-associatedplasmin.Arterioscler Thromb I3:48, I993 50. Urano T, Sator de Serrano V, Chibber BAK, Castellino FJ: The control of the urokinase-catalyzed activation of human glutamic acid l-plasminogen by positive and negative effectors. J Biol Chem 262: 15959, I987 5 1. Myohanen HT, Stephens RW, Hedman K, Tapiovaara H, Rdnne E, H~yer-HansenG , Dan6 K, Vaheri A: Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. J Histochem Cytochem4 1:129I , 1993 52. Hajjar KA, Hamel NM, Harpel PC, Nachman R L Binding oftissue plasminogen activator to cultured human endothelialcells. J Clin Invest 80: 17 12, 1987
© Copyright 2024